Searching News Database: Shire Plc
HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
HSMN NewsFeed - 4 Apr 2018
Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018
Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018
HSMN NewsFeed - 5 Mar 2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
HSMN NewsFeed - 3 Oct 2017
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
HSMN NewsFeed - 1 Sep 2016
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
HSMN NewsFeed - 24 Mar 2016
Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors
Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors
HSMN NewsFeed - 8 Apr 2015
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
HSMN NewsFeed - 24 Nov 2014
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
HSMN NewsFeed - 19 May 2014
Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
HSMN NewsFeed - 5 May 2014
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
HSMN NewsFeed - 1 Apr 2014
Trevena Appoints Robert Prachar as Senior Vice President, Commercial and Corporate Strategy
Trevena Appoints Robert Prachar as Senior Vice President, Commercial and Corporate Strategy
HSMN NewsFeed - 11 Dec 2013
Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
HSMN NewsFeed - 8 Feb 2013
Impax and Shire Settle Litigation Concerning Supply of Authorized Generic Adderall XR(R)
Impax and Shire Settle Litigation Concerning Supply of Authorized Generic Adderall XR(R)
HSMN NewsFeed - 15 Nov 2012
Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
HSMN NewsFeed - 27 Mar 2012
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
HSMN NewsFeed - 18 Nov 2011
Shire Announces Strategic Partnership for ADHD Medicines in Japan With Shionogi & Co., Ltd.
Shire Announces Strategic Partnership for ADHD Medicines in Japan With Shionogi & Co., Ltd.
HSMN NewsFeed - 9 Sep 2010
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
HSMN NewsFeed - 28 Oct 2009
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
HSMN NewsFeed - 26 Oct 2009
FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
HSMN NewsFeed - 7 Oct 2009
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
HSMN NewsFeed - 16 Jul 2009
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
HSMN NewsFeed - 2 Apr 2009
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
HSMN NewsFeed - 20 Mar 2009
Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
HSMN NewsFeed - 16 Mar 2009
Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
HSMN NewsFeed - 9 Feb 2009
Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
HSMN NewsFeed - 3 Sep 2008
Rib-X Pharmaceuticals, Inc. Appoints Dr. Joseph Amprey of MedImmune Ventures to Board of Directors
Rib-X Pharmaceuticals, Inc. Appoints Dr. Joseph Amprey of MedImmune Ventures to Board of Directors
HSMN NewsFeed - 15 Jul 2008
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
HSMN NewsFeed - 11 Sep 2007
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
HSMN NewsFeed - 6 Sep 2007
Shire Appoints Anita Graham to the Newly Created Position of Chief Administrative Officer
Shire Appoints Anita Graham to the Newly Created Position of Chief Administrative Officer
HSMN NewsFeed - 8 Aug 2007
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
HSMN NewsFeed - 16 May 2007
Halozyme Therapeutics Names Randal J. Kirk and Kathryn E. Falberg to Board of Directors
Halozyme Therapeutics Names Randal J. Kirk and Kathryn E. Falberg to Board of Directors
HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
HSMN NewsFeed - 20 Nov 2006
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
HSMN NewsFeed - 13 Nov 2006
Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Additional items found! 21
Members Archive contains
21 additional stories matching:
Shire Plc
(Password required)
Shire Plc
(Password required)